Background. There are several case reports of rhabdomyolysis (RM) in renal transplant recipients, but the actual incidence of this complication is not known. Most of the reported cases have been attributed to drugdrug interactions with calcineurin inhibitors, with the majority of interactions reported between cyclosporine and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). Pharmacokinetic studies have demonstrated that cyclosporine increases statin drug levels, presumably via competitive inhibition of cytochrome P450 3A4. Methods. In a retrospective cohort of 20 366 adult Medicare primary renal transplant recipients in the USRDS database transplanted from 1 January 2003 to 31 July 2005 and followed through 31 December 2005, we assessed Medicare claims for RM and dyslipidaemia (HPL), which was used as a surrogate for statin use. Conclusions. RM is a rare complication after renal transplantation and is significantly associated with allograft loss (including death). RM is significantly more likely to occur with cyclosporine (versus tacrolimus)-based immunosuppression and possibly in persons of black race. Increased surveillance for RM is warranted in these at-risk patients.
Introduction
There are several case reports of rhabdomyolysis (RM) in renal transplant recipients, but the actual incidence of this complication is not known. Most of the reported cases have been attributed to drug-drug interactions with calcineurin inhibitors (CNI), with the majority of interactions reported between cyclosporine and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins). Cases have been reported in cyclosporine-treated patients taking simvastatin [1] [2] [3] , cerivastatin [4, 5] and atorvastatin [6] . In contrast, only two cases of RM were found in renal transplant patients treated with tacrolimus and statin drugs, and these cases had other potential aetiologies of RM to include prolonged, tonic-clonic seizures [7] and use of fusidic acid [8] .
Several pharmacokinetic studies have been done to evaluate the interaction between cyclosporine and statin drugs. In these studies, use of cyclosporine has been shown to increase drug levels of most statin drugs, with increases in area under the curve (AUC) concentrations ranging from 2-to 20-fold, depending on statin drug tested. The exact mechanism for this is unknown, but is thought be related to competition for cytochrome P450 3A4 enzyme metabolism, which results in increased statin drug levels, potentially enhancing their toxicity [9, 10] . Of note, several statin drugs are not metabolized via this pathway (fluvastatin, pravastatin) and may be less likely to have elevated drug levels when used with cyclosporine [11, 12] .
Current guidelines for treating dyslipidaemia (HPL) in renal transplant recipients recommend treating low density lipoprotein (LDL) >100 mg/dL with statin therapy in addition to therapeutic lifestyle changes to reduce cardiovascular morbidity and mortality [10, 13] , and as many as 50% of renal transplant recipients were treated with statins as of 1996 [14] . Presumably, statins are now used more frequently and at higher doses to achieve recommended LDL targets.
Even with a high prevalence of statin use in this population, RM is presumably a rare complication. However, to date, there are no large-scale studies on the epidemiology of RM after renal transplantation. Thus, the goals of this study were to determine the incidence of RM in this population, to determine specific risk factors for RM, and to determine the effect of RM on allograft outcome.
Materials and methods

Patients and sources
This study used the United States Renal Data System (USRDS) database, which incorporates extensive baseline and follow-up demographic and clinical data on all patients accessing the Medicare ESRD program in the United States. The variables included in the USRDS standard analysis files (SAFs), as well as methods and validation studies, are published and listed at the USRDS website, under 'Researcher's Guide to the USRDS Database', Section E, 'Contents of all the SAFs'. The demographics of the renal transplant population have been previously described (2006 USRDS report). The files SAF.TXUNOS were used as the primary dataset. We used an inception cohort (based on date of transplant) with patients over age 18 who underwent renal transplantation between 1 January 2003 and 31 July 2005 and had Medicare primary insurance (parts A&B).
Outcome variables
The outcome variables were based on Institutional claims reported to Medicare from 1 January 1999 to 31 December 2005. The claims were identified by International Classification of Diseases-9th Revision Diagnosis Codes (ICD9). Primary outcome variable was RM (ICD9 code: 728.88) with allograft loss (including death) as a secondary outcome variable. We assessed the earliest Medicare claim for RM after transplantation and excluded patients who had pre-transplant claims. Of note, the ICD9 diagnostic code for RM was introduced in December 2002 and implemented in October 2003.
Survival times
Time to RM was calculated as the time from transplant date until the date of first Medicare claim for RM, with recipients censored at time of death, loss to follow-up or the end of the study period (31 December 2005) .
Independent variables
Patient characteristics were those at the date of transplant, with the exception of data from the Centers for Medicare and Medicaid Services (CMS) Form 2728, which includes demographic and comorbidity data obtained at the first treatment for ESRD, whether dialysis or transplant. The duration of dialysis (dialysis vintage) pre-transplant was defined as the time from first recorded dialysis treatment until the date of transplantation. Other variables assessed included donor and recipient age, race, gender, induction/maintenance immunosuppressants, graft loss, delayed graft function (DGF), human leukocyte antigen (HLA) match status, panel reactive antibody (PRA), cold ischaemic time (CIT), expanded donor criteria (ECD), donation after cardiac death (DCD), human immunodeficiency virus (HIV) status and deceased-donor transplant (CRT). Data from CMS form 2728 included information on comorbid conditions including diabetes mellitus (DM), ischaemic heart disease (IHD), congestive heart failure (CHF), peripheral vascular disease (PVD), acquired immunodeficiency syndrome (AIDS), alcohol dependence and tobacco use.
To assess for HPL in this population, we identified Medicare claims using ICD9 codes (272-272. 4, 272.8-272.9) . In order to minimize bias, we differentiated between pre-transplant HPL (earliest Medicare claim for HPL prior to renal transplantation) and post-transplant HPL (HPL after transplantation, but before RM diagnosis). Because HPL codes posttransplant were limited by both surveillance bias and immortal time bias, pre-transplant HPL was used in the primary analysis. As a sensitivity analysis, we evaluated post-transplant HPL using a propensity score of factors associated with cyclosporine (versus tacrolimus) use, which would not have been subject to the temporal biases of including post-transplant HPL alone.
Because data on use of non-immunosuppressant drugs are not available in the USRDS database, HPL was used as a surrogate marker of statin use. Of note, for the purposes of this study, cyclosporine includes only the microemulsion formulation (Neoral R ) in order to facilitate direct comparison with tacrolimus, which is also non-generic in order to avoid potential unmeasured confounders that may be associated with the use of generic immunosuppressive drugs.
Statistical analysis
All analyses were performed using SPSS 12.0 TM (SPSS, Inc., Chicago, IL). Files were merged and converted to SPSS files using DBMS/Copy (Conceptual Software, Houston, TX, USA). Bivariate analysis of factors associated with RM was performed with chi-square testing for categorical variables (Fisher's exact test used for violations of Cochran's assumptions) and Student's t-test for continuous variables (Mann-Whitney test used for non-normally distributed variables), respectively. Statistical significance for bivariate comparisons was defined as P < 0.05.
The independent associations between patient factors and RM were examined using multivariate analysis with forced entry Cox regression. Variables with P < 0.10 tested in bivariate analysis for a relationship were entered into multivariate analysis as covariates, because of the possibility of negative confounding. Variables thought to have a known clinical association with outcomes (HPL as a surrogate for statin use) were also introduced into multivariate models even if bivariate P-values were >0.10, in accordance with established principles of model development. In a sensitivity analysis, propensity scores were obtained (adjusting for recipient and donor age, gender, donor type, dialysis vintage, DM, post-transplant HPL, HLA mismatch and peak PRA) to adjust for potential confounding non-random factors associated with the use of cyclosporine (versus tacrolimus) [15] .
The association between renal allograft loss (including death) and RM as a time-dependent variable was assessed with Cox non-proportional hazards regression. Variables found to be independently associated with RM in the above Cox regression were included in the model as were factors known to be independently associated with allograft loss (recipient age, black race, PRA >20%, dialysis vintage, DM, CHF, IHD, PVD, tobacco use, HLA matching, donor age >50, donor black race, CRT, ECD, DCD, DGF, CIT >24 h, year of transplant, and induction/discharge immunosuppression). Kaplan-Meier analysis was used to plot time to RM for patients who were treated with cyclosporine (versus tacrolimus). The log-rank test was used for bivariate significance testing. Otherwise, patients were censored at time of death, loss to follow-up or the end of the study period.
Results
We identified 20 379 Medicare primary renal transplant recipients transplanted from 1 January 2003 to 31 July 2005. There were 13 patients with prior Medicare claims for RM, leaving 20 366 patients to be included in the analysis. The mean age was 49.6 ± 15.6 years, and 29.7% were of black race. The mean dialysis vintage was 3.5 ± 2.9 years prior to transplant, and the mean follow-up after transplant (until graft loss or death or end of study period) was 2.19 ± 0.93 years (Table 1) . Among the 20 366 transplant patients without prior evidence of RM, there were 62 individual cases of RM with a cumulative incidence of 0.3% and an incidence rate of 1.4 (95% CI 1.1-1.8) cases per 1000 person-years or 137 (95% CI 106-175) cases per 100 000 person-years. The mean time to diagnosis of RM was 1.08 ± 0.72 years after transplant.
Patients diagnosed with RM were older and more likely to have DM. Of note, there was no significant association with RM and HPL, whether diagnosed before or after transplant. Patients with RM were more likely to be discharged on cyclosporine therapy and less likely to be discharged with tacrolimus (Table 1) . Pre-transplant HPL (as a surrogate marker for statin use) was not associated with RM on either bivariate (Table 1) or multivariate (Table 2) analysis. There was also no significant association on Kaplan-Meier time to event plot (log rank P = 0.145) (Figure 2 ). Sirolimus, which is known to be associated with post-transplant HPL, was not associated with RM on either bivariate (Table 1) or multivariate analysis [AHR 0.56 (CI 0.24-1.31)] in this study.
Discussion
The incidence rate of RM in this population was 137 (95% CI 106-175) cases per 100 000 person-years, which is elevated compared with data on drug-induced RM in the general population. Based on pooled data from 20 randomized trials, the incidence of statin-induced RM in the general population is reported to be 3.4 (95% CI 1.6-6.5) per 100 000 person-years [16] . This incidence has been shown to increase 10-fold when statins are used in combination with other potentially myopathic drugs [17] . For example, the incidence rate for the statin-gemfibrozil com- bination is 35 (95% CI 1-194) per 100 000 person-years [16] . Unfortunately, we were not able to assess for the use of statins or other potentially myopathic drugs possibly used in combination with CNIs in our study due to database limitations. Regardless of aetiology, this increased incidence of RM compared with the general population deserves further exploration.
There is minimal existing epidemiologic data on the frequency of RM in the renal transplant population. In an observational study of 12 renal transplant patients taking cyclosporine and lovastatin, aymptomatic RM occurred in one patient (8.3%) after 3 months of lovastatin therapy. Allograft function was not impaired, and the patient was safely restarted on a lower dose of lovastatin once his serum creatinine kinase (CK) and myoglobin normalized [18] . In the Assessment of Lescol in Renal Transplantation (ALERT) study, a much larger study with 2102 patients, two patients (0.1%) developed non-fatal RM (one in each group) over a mean of 5.1 ± 1.1 years of follow-up with an incidence rate of 19 (95% CI 0.3-62) cases per 100 000 person-years. However, both episodes of RM were attributed to severe trauma and not the study medication. After resolution of RM, both patients were safely restarted on their respective treatments and completed the study [19] . Of note, this trial used fluvastatin, which as above, is thought to have less of an effect on statin drug levels when used with cyclosporine [11, 12] .
In our study, cyclosporine (versus tacrolimus) use was significantly associated with RM. This is consistent with the observation that cyclosporine was the primary CNI used in the majority of case reports of RM in the renal transplant population. There are several possible explanations for this observation. First, several pharmacokinetic studies have demonstrated that cyclosporine increases statin drug levels [10] . In contrast to cyclosporine, only limited data exists on the interaction between tacrolimus and statins. In a study that compared cyclosporine with tacrolimus in patients receiving simvastatin, both peak and AUC concentrations of simvastatin increased 8-fold with cyclosporine, whereas there was no significant change when simvastatin was given in combination with tacrolimus [20] . In a similar study comparing cyclosporine with tacrolimus in patients taking atorvastatin, tacrolimus had no effect on atorvastatin pharmacokinetics, while cyclosporine increased levels of atorvastatin and its metabolites [21] . However, this may be dependent on the specific statin used since tacrolimus was shown to increase levels of cerivastatin by a mean of 35% in a different study [22] . As stated above, there are reports of RM with tacrolimus use in renal transplant recipients. However, in the RM cases reported with tacrolimus, there are other plausible explanations for RM to include prolonged, tonic-clonic seizures [7] , and use of fusidic acid [8] .
A second possible explanation is that HPL is a frequent complication of cyclosporine therapy. This adverse effect could obligate statin use and possibly necessitate higher statin dosing, both of which would presumably increase the risk of RM. Arguing against this explanation is that sirolimus (which arguably causes more HPL than cyclosporine) was not associated with RM on either bivariate (Table 1) or multivariate analysis [AHR 0.56 (CI 0.24-1.31)] in this study. However, while sirolimus can cause HPL, the interaction between sirolimus and statins is unknown [10] .
The association of RM with black race is intriguing and has not been previously reported. Based on the previous literature, black patients are only known to have increased risk of developing RM if they have sickle cell trait [23] [24] [25] . While this could represent a true difference in risk because of ethnic differences in drug metabolism or drug-drug interaction, it could also be a result of positive confounding (i.e. positive statistical significance because of the influence of other unmeasured factors). For example, black patients may have been deemed higher risk for acute rejection and treated with higher doses of CNI.
Limitations
Because ICD9 codes (instead of clinical data) were used to define RM, it is possible that only the more severe cases were detected, which could underestimate the true incidence of disease. However, using these Institutional (i.e. hospitalized) Medicare Claims could also strengthen the results by only including the more severe, clinically relevant cases. Since the ICD9 code for RM was implemented in October 2003, it is possible that cases diagnosed prior to this were missed, also leading to an underestimate of the true incidence of disease.
Unfortunately, statin use is not tracked by the USRDS, and there is no data regarding specific statin drugs or doses used in this population. We attempted to use HPL as a surrogate for statin use with HPL defined by ICD9 codes, but this methodology has several limitations. This method relies on the assumption that patients with a diagnosis of HPL are likely to be taking statin drugs, which may not always be true; in dialysis patients there is no proven survival benefit of statin drugs in the treatment of HPL [26] . Also, using ICD9 codes (as opposed to laboratory studies) to define HPL likely leads to an underestimation of true HPL similar to observations in chronic kidney disease [27, 28] . Because HPL codes post-transplant result in both surveillance bias (i.e. patients had to be seen by a physician to be diagnosed) and immortal time bias (i.e. patients had to survive to be diagnosed), we felt that using pre-transplant HPL was a more appropriate method since it is not subject to these temporal limitations. However, this technique also likely underestimates true HPL, since it is complicated by coverage bias in that diagnostic codes for HPL would require Medicare coverage prior to transplantation. We attempted to address this issue in our sensitivity analysis using a propensity score of factors (including post-transplant HPL) associated with cyclosporine (versus tacrolimus) use, which would not have been subject to the temporal biases of including post-transplant HPL alone.
Given that we cannot account for statins or other medications that could potentially interact with CNIs to cause RM, it is possible that unmeasured confounders could account for the significant associations noted. In several of the reported cases of RM in patients taking cyclosporine and statins, other medications were implicated as causing or contributing to RM. Some examples include colchicine [29, 30] , levofloxacin [29] , itraconazole [31] , mibefradil [32] and clarithromycin [2] . Current recommendations state that addition of a third agent (in addition to CNI and statins) metabolized by the cytochrome P450 system should be avoided [10] , although sometimes clinical practice necessitates their use. It is also possible that cases of RM were not associated with drugs and could have been secondary to trauma, seizures, etc.
Limitations specific to the methods of USRDS database research have been previously described [33] . Briefly, we are using an administrative database, and it is possible that data may be missing or incomplete. While data entry is standardized and performed centrally, raw data are collected from multiple centres and there could be a lack of standardization or misclassification of key variables. Also, as above, certain clinical information which would have been pertinent to this study are not routinely included in this database.
Conclusion
In summary, RM is a rare complication after renal transplantation, but seems to occur at a greater frequency compared with the general population. Regardless of aetiology, this issue deserves further exploration. We were unable to accurately account for the use of statins or other myopathic drugs, but did find that RM was significantly more likely to occur with cyclosporine (versus tacrolimus)-based immunosuppression and possibly in persons of black race. Because RM after renal transplantation is significantly associated with renal allograft loss (including death), increased surveillance for RM is warranted in these at-risk patients.
